Abeona Therapeutics (ABEO) vs Korro Bio (KRRO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Korro Bio (KRRO) has outperformed Abeona Therapeutics (ABEO) over the past year, gaining 93.9% versus a loss of 46.0%. Over five years, ABEO leads with a -86.7% price change compared with -95.7% for KRRO. Korro Bio is the larger company by market cap ($167.2 million vs $165.3 million), about 1.0 times the size.
Abeona Therapeutics converts more of its revenue into profit, with a net margin of 1223.1% versus -1834.5%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ABEO | KRRO |
|---|---|---|
| Share price | $2.42 | $12.18 |
| Market cap | $165.31M | $167.18M |
| 1-day change | -1.22% | -0.08% |
| YTD return | -54.08% | +52.06% |
| 1-year return | -45.98% | +93.95% |
| 5-year return | -86.74% | -95.67% |
| EPS (TTM) | $-1.16 | $-8.89 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $5.82M | $6.39M |
| Revenue growth (YoY) | — | +181.46% |
| Net income (latest FY) | $71.18M | $-117.26M |
| Gross margin | 73.68% | — |
| Operating margin | -1536.91% | -1906.37% |
| Net margin | 1223.08% | -1834.48% |
| 52-week high | $7.65 | $17.35 |
| 52-week low | $2.09 | $5.20 |
| Distance from 52-week high | -68.37% | -29.81% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +542.98% | +76.52% |
| Average volume | 1.66M | 186.03K |
| Shares outstanding | 68.31M | 13.73M |
| Employees | 226 | 58 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- KRRO has outperformed ABEO by 139.9 percentage points over the past year.
- Abeona Therapeutics is more profitable, keeping 1223.1 cents of every revenue dollar as net income versus -1834.5 cents for Korro Bio.
About Abeona Therapeutics
ABEO stock →Abeona Therapeutics Inc., a commercial-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases in the United States. It develops ZEVASKYN, an autologous, cell-based gene therapy for the treatment of patients with recessive dystrophic epidermolysis bullosa.
Health Care · Biotechnology: Pharmaceutical Preparations · 226 employees
About Korro Bio
KRRO stock →Korro Bio, Inc., a biopharmaceutical company, engages in the discovering, developing, and commercializing of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases in the United States. The company's lead product candidate is KRRO-121 for the treatment for hyperammonemia.
Health Care · Biotechnology: Pharmaceutical Preparations · 58 employees
ABEO vs KRRO FAQ
Which is bigger, Abeona Therapeutics or Korro Bio?
Korro Bio (KRRO) is larger, with a market capitalization of $167.18M compared with $165.31M for Abeona Therapeutics (ABEO).
Which stock has performed better over the past year, ABEO or KRRO?
KRRO returned +93.95% over the past 12 months, compared with -45.98% for ABEO (price return, excluding dividends). Past performance does not predict future results.
Are Abeona Therapeutics and Korro Bio in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.